R&D channel feed – Endpoints News

R&D channel feed

BioMarin scales back launch for hemophilia gene therapy, pitches path to profitability

10 months ago

Eliot Forster’s pain biotech unveils Phase 2 data in degenerative joint disease

10 months ago

Nuvation pauses BET inhibitor plans after checking out interim Phase 1 data

10 months ago

Q&A: Genentech's new CEO on AI, IRA and radiopharma

10 months ago

FDA wants new trial of Actinium’s radioactive iodine drug, company to seek partner

10 months ago

Bayer plans label expansion for Kerendia after Phase 3 win in heart failure

10 months ago

BioNTech says no to Phase 3 with Genmab’s bispecific antibody

10 months ago

Bristol Myers returns TIGIT bispecific to Agenus, frees itself from $1B+ milestones

10 months ago

Advisory committee votes in favor of Zevra Therapeutics' rare genetic disease drug

10 months ago

Massachusetts' plan for $1B in life science investment stalls in state legislature

10 months ago

Iron chelator therapy unexpectedly worsened Alzheimer’s disease in clinical study

10 months ago

Galapagos pauses blood cancer CAR-T therapy trial due to one Parkinsonism event

10 months ago

Agios' late-stage Pyrukynd trial in kids with rare blood disorder misses primary endpoint

10 months ago

Vertex says about 20 patients have started sickle cell therapy, cuts two rare disease programs

10 months ago

Arbutus reduces headcount after axing HBV combo trial that features Imfinzi

10 months ago

Updated: Jim Wilson to step down from gene therapy post at UPenn, will form two new companies

10 months ago

It took more than two decades for MDMA to reach the FDA. In two months, its prospects cracked. What happens next?

10 months ago

Updated: Eli Lilly’s tirzepatide reduces risk of heart failure outcomes in Phase 3 study

10 months ago

Sage changes main endpoint in Huntington's study months ahead of readout

10 months ago

ALX Oncology continues its CD47 quest, revealing Phase 2 gastric cancer data

10 months ago

Takeda defends Alzheimer's pact, TYK2 potential as restructuring is in 'full swing'

10 months ago

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

10 months ago

Updated: Eisai says Alzheimer's drug keeps working after three years. But weaknesses in study raise questions

10 months ago

MacroGenics stops further dosing in Phase 2 prostate cancer drug trial

10 months ago

First page Previous page 33 34 353637 38 39 Next page Last page